Clinical trial · no report yet · Phase 3
VERIFY
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
- NCT05210790 ↗
- Active not recruiting
- Protagonist Therapeutics, Inc.
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients With Polycythemia Vera
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Polycythemia Vera
- Interventions
- Placebo; Rusfertide
- Arms
- Rusfertide · Experimental
- Placebo · Experimental
- Enrollment
- 293
- Primary outcomes
- Proportion of subjects achieving a response who receive rusfertide compared to placebo.
- Sponsor
- Protagonist Therapeutics, Inc.
- Start
- Apr 1, 2022
- Primary completion
- Feb 21, 2025
- Results posted
- No
- Registry record
- NCT05210790 · updated Aug 7, 2025